ArticleNPJ precision oncology2025

Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers.

Daehwan Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.